vs
Side-by-side financial comparison of DONEGAL GROUP INC (DGICA) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($346.4M vs $236.0M, roughly 1.5× DONEGAL GROUP INC). HAEMONETICS CORP runs the higher net margin — 28.1% vs 4.9%, a 23.2% gap on every dollar of revenue. On growth, HAEMONETICS CORP posted the faster year-over-year revenue change (4.8% vs -3.7%). Over the past eight quarters, HAEMONETICS CORP's revenue compounded faster (1.5% CAGR vs -2.2%).
Donegal Group Inc. is a regional US insurance holding company offering personal and commercial property and casualty insurance products. It serves Mid-Atlantic, Midwest, and Southern US customers, delivering tailored coverage for individuals, families, and small to medium businesses.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
DGICA vs HAE — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2026
| Metric | | |
|---|---|---|
| Revenue | $236.0M | $346.4M |
| Net Profit | $11.5M | $97.3M |
| Gross Margin | — | 57.2% |
| Operating Margin | — | 36.1% |
| Net Margin | 4.9% | 28.1% |
| Revenue YoY | -3.7% | 4.8% |
| Net Profit YoY | -54.3% | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $236.0M | $346.4M | ||
| Q4 25 | $239.8M | $339.0M | ||
| Q3 25 | $245.9M | $327.3M | ||
| Q2 25 | $247.1M | $321.4M | ||
| Q1 25 | $245.2M | $330.6M | ||
| Q4 24 | $250.0M | $348.5M | ||
| Q3 24 | $251.7M | $345.5M | ||
| Q2 24 | $246.8M | $336.2M |
| Q1 26 | $11.5M | $97.3M | ||
| Q4 25 | $17.2M | $44.7M | ||
| Q3 25 | $20.1M | $38.7M | ||
| Q2 25 | $16.9M | $34.0M | ||
| Q1 25 | $25.2M | $58.0M | ||
| Q4 24 | $24.0M | $37.5M | ||
| Q3 24 | $16.8M | $33.8M | ||
| Q2 24 | $4.2M | $38.4M |
| Q1 26 | — | 57.2% | ||
| Q4 25 | — | 59.7% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 59.8% | ||
| Q1 25 | — | 58.4% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 54.2% | ||
| Q2 24 | — | 52.0% |
| Q1 26 | — | 36.1% | ||
| Q4 25 | 8.7% | 19.9% | ||
| Q3 25 | 10.2% | 17.9% | ||
| Q2 25 | 8.3% | 16.8% | ||
| Q1 25 | 12.7% | 21.6% | ||
| Q4 24 | 11.9% | 16.9% | ||
| Q3 24 | 8.1% | 15.0% | ||
| Q2 24 | 2.0% | 11.8% |
| Q1 26 | 4.9% | 28.1% | ||
| Q4 25 | 7.2% | 13.2% | ||
| Q3 25 | 8.2% | 11.8% | ||
| Q2 25 | 6.8% | 10.6% | ||
| Q1 25 | 10.3% | 17.5% | ||
| Q4 24 | 9.6% | 10.8% | ||
| Q3 24 | 6.7% | 9.8% | ||
| Q2 24 | 1.7% | 11.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | $0.95 | ||
| Q3 25 | — | $0.81 | ||
| Q2 25 | — | $0.70 | ||
| Q1 25 | — | $1.17 | ||
| Q4 24 | — | $0.74 | ||
| Q3 24 | — | $0.66 | ||
| Q2 24 | — | $0.74 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $245.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $649.1M | $796.3M |
| Total Assets | $2.4B | $2.4B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $245.4M | ||
| Q4 25 | — | $363.4M | ||
| Q3 25 | — | $296.4M | ||
| Q2 25 | — | $292.9M | ||
| Q1 25 | — | $306.8M | ||
| Q4 24 | — | $320.8M | ||
| Q3 24 | — | $299.3M | ||
| Q2 24 | — | $344.4M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $649.1M | $796.3M | ||
| Q4 25 | $640.4M | $911.5M | ||
| Q3 25 | $627.4M | $849.2M | ||
| Q2 25 | $605.7M | $882.3M | ||
| Q1 25 | $584.7M | $820.8M | ||
| Q4 24 | $545.8M | $906.9M | ||
| Q3 24 | $513.4M | $878.9M | ||
| Q2 24 | $484.1M | $905.4M |
| Q1 26 | $2.4B | $2.4B | ||
| Q4 25 | $2.4B | $2.5B | ||
| Q3 25 | $2.4B | $2.4B | ||
| Q2 25 | $2.4B | $2.5B | ||
| Q1 25 | $2.4B | $2.5B | ||
| Q4 24 | $2.3B | $2.5B | ||
| Q3 24 | $2.3B | $2.5B | ||
| Q2 24 | $2.3B | $2.5B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 1.44× | ||
| Q2 25 | — | 1.39× | ||
| Q1 25 | — | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $293.2M |
| Free Cash FlowOCF − Capex | — | $209.9M |
| FCF MarginFCF / Revenue | — | 60.6% |
| Capex IntensityCapex / Revenue | — | 9.5% |
| Cash ConversionOCF / Net Profit | — | 3.01× |
| TTM Free Cash FlowTrailing 4 quarters | — | $417.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $293.2M | ||
| Q4 25 | $70.2M | $93.6M | ||
| Q3 25 | $22.4M | $111.3M | ||
| Q2 25 | $12.1M | $17.4M | ||
| Q1 25 | $25.7M | $116.6M | ||
| Q4 24 | $67.4M | $43.8M | ||
| Q3 24 | $12.7M | $48.8M | ||
| Q2 24 | $21.7M | $-27.4M |
| Q1 26 | — | $209.9M | ||
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M |
| Q1 26 | — | 60.6% | ||
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% |
| Q1 26 | — | 9.5% | ||
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% |
| Q1 26 | — | 3.01× | ||
| Q4 25 | 4.08× | 2.09× | ||
| Q3 25 | 1.11× | 2.88× | ||
| Q2 25 | 0.72× | 0.51× | ||
| Q1 25 | 1.02× | 2.01× | ||
| Q4 24 | 2.81× | 1.17× | ||
| Q3 24 | 0.76× | 1.44× | ||
| Q2 24 | 5.22× | -0.71× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DGICA
Segment breakdown not available.
HAE
| Hospital | $159.6M | 46% |
| Plasma | $130.3M | 38% |
| Blood Center | $56.4M | 16% |
